China 
Africa 
Explore chapters and articles related to this topic
Anti-Inflammatory Dendrimers
Published in Delphine Felder-Flesch, Dendrimers in Nanomedicine, 2016
Cédric-Olivier Turrin, Anne-Marie Caminade
Despite the fact that the search for new anti-inflammatory drugs is an area of strong interest, it should be noted that the literature related to dendrimer-based anti-inflammatory strategies is rather scarce, although it has been significantly increasing over the last few years. This observation can possibly be related to the fact that traditional drug discovery like structure-based drug design, has been moderately successful in satisfying the unmet needs related to chronic inflammation, possibly because of the extreme complexity of immune responses underlying inflammatory processes and the high development costs associated to traditional drug discovery pathways. Drug repositioning, that is finding new uses for existing drugs, is actually an option that is preferred by big pharmaceutical companies and smaller biotechnology companies, because it offers faster development times and costs. This tendency can be illustrated by the presence of many MoAbs originating from the oncology pipeline in several clinical assays for the treatment of CIDs, despite the severe and deleterious side effects associated to these biologics-based treatments.
Application of Computational and Bioinformatics Techniques in Drug Repurposing for Effective Development of Potential Drug Candidate for the Management of COVID-19
Published in Hajiya Mairo Inuwa, Ifeoma Maureen Ezeonu, Charles Oluwaseun Adetunji, Emmanuel Olufemi Ekundayo, Abubakar Gidado, Abdulrazak B. Ibrahim, Benjamin Ewa Ubi, Medical Biotechnology, Biopharmaceutics, Forensic Science and Bioinformatics, 2022
Charles Oluwaseun Adetunji, Olaniyan Tope Olugbemi, Muhammad Akram, Umme Laila, Michael Olugbenga Samuel, Ayomide Michael Oshinjo, Juliana Bunmi Adetunji, Gloria E. Okotie, Nwadiuto (Diuto) Esiobu, Omotayo Opemipo Oyedara, Folasade Muibat Adeyemi
Drug repositioning is a method of identifying new therapeutic drugs from previously existing ones as well as determining remedies for untreated pathogens (Jarada et al., 2020). This method is time saving and cost effective for developing therapies in basic medical sciences compared to the conventional drug discovery de novo methods. Drug repositioning requires large public health, biological, and biomedical data together with highly skilled computational physiologists to hasten the process (Jarada et al., 2020). Furthermore, network-based approaches can be utilized to predict drug target for repurposing and repositioning; thus, integrated data set could be used for evaluation metrics for research and treatment outcomes (Lotfi et al., 2017).
DNA-interaction studies of a copper(II) complex containing ceftobiprole drug using molecular modeling and multispectroscopic methods
Published in Journal of Coordination Chemistry, 2018
Nahid Shahabadi, Soraya Moradi Fili
The introduction of a new drug from initial concept to public release is a slow expensive process. Developing a new chemical entity drug and delivering it to market is estimated to take 10–17 years and cost ∼$1.8 billion [1]. Alternative strategies are therefore needed and the process of drug repositioning or repurposing, where new applications for existing drugs or drug candidates are discovered and refined, has become increasingly common. Drug repurposing can speed up access to new therapeutic options for cancer patients. With more than 2,000 drugs approved worldwide and 6 relevant targets per drug on average, the potential is quantitatively important. Hence, we propose that a more plausible and faster approach is the utilization of drugs originally developed for other purposes besides antimicrobial activity. Among these, there are some antibiotics which their most common mode of action is the inhibition of cell wall synthesis.